Compare Gilead Sciences, Inc. (GILD) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Xcel Energy Inc — how do they compare? Gilead Sciences, Inc. trades at $137.03 (market cap $168.35B), while Xcel Energy Inc trades at $78.28 (market cap $48.51B). The key difference: Gilead Sciences, Inc. is far larger — about 3.5× Xcel Energy Inc's market cap, and Xcel Energy Inc pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| GILD | XEL | |
|---|---|---|
Market Cap | $168.35B | $48.51B |
Sector | Health | Utilities |
52-Week High | $155.80 | $83.91 |
52-Week Low | $110.56 | $71.75 |
Enterprise Value | $191.42B | $86.82B |
Dividend Yield | 2.42% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Xcel Energy (XEL) trades at $76.87, down 1.54% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, and maintains a solid dividend. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%, while analyst consensus is bullish with a $93.80 price target.
The outlook is supported by earnings growth and a $60 billion capital investment plan, but risks include regulatory pushback and high debt levels. The stock offers a stable investment opportunity with growth potential from infrastructure spending, though affordability concerns and interest rate sensitivity pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
